Review by a blinded independent radiology review committee (IRC) has confirmed the progression-free survival (PFS) results from the phase II CABOSUN trial, which compares first-line cabozantinib with sunitinib in patients with advanced renal cell carcinoma (RCC). Cabozantinib demonstrated a clinically meaningful and statistically significant reduction in the rate of disease progression or death as measured by PFS. The manufacturer, Ipsen plans to submit the regulatory dossier for cabozantinib as a first-line treatment for advanced renal cell carcinoma in Europe in the third quarter of 2017.

Read more here

Read the Nasdaq article here